探讨影响妇科恶性肿瘤患者术后睡眠的围术期因素——以镇静药物选择为例的假说与证据缺口分析

Perioperative Factors Affecting Postoperative Sleep in Patients with Gynecological Malignancies—Hypotheses and Evidence Gaps Illustrated by the Choice of Sedative Agents

摘要: 妇科恶性肿瘤患者在术前已可能存在癌症相关失眠、焦虑抑郁、疼痛和昼夜节律紊乱；手术创伤、麻醉残余、阿片暴露、恶心呕吐、夜间护理及住院环境又会叠加形成术后睡眠障碍。睡眠障碍与痛觉敏化、炎症反应、谵妄风险、活动恢复和生活质量相互影响，是加速康复的重要临床环节。本文不再将瑞马唑仑与咪达唑仑简单排序，而是提出“药物选择通过苏醒、残余镇静、血流动力学和呼吸效应间接影响睡眠”的可检验假说，并系统梳理围术期疼痛、心理压力、手术方式、加速康复(ERAS)和病房环境等决定因素。苯二氮䓬类药物仍是围术期镇静和麻醉辅助的重要药物，其中瑞马唑仑为经组织酯酶快速代谢的超短效苯二氮䓬类药物，咪达唑仑则具有起效快、抗焦虑和顺行性遗忘等特点，但两者对术后睡眠结构、次日清醒度及长期睡眠质量的影响可能不同。现有直接证据仅来自未按恶性肿瘤分层的妇科腹腔镜研究：一项132例随机试验显示，瑞马唑仑组术后首夜总睡眠时间及深睡比例低于丙泊酚组，且苏醒和PACU离室较慢；另一项老年妇科腹腔镜研究提示睡眠障碍减少，但公开资料对样本量和效应量报告有限。在结直肠癌老年患者中，瑞马唑仑–丙泊酚联合方案与较短苏醒时间和较低睡眠障碍发生率相关，但该结果不能替代瑞马唑仑–咪达唑仑头对头证据。程序镇静试验显示瑞马唑仑较咪达唑仑起效和清醒更快、术后额外嗜睡更少，但其剂量和临床场景与根治性妇科肿瘤手术不同。本文围绕妇科恶性肿瘤患者术后睡眠障碍的特点，结合药理学基础与现有临床证据，深入分析当前研究的方法学局限与证据缺口，明确指出当前证据支持开展分层、充分设盲、统一ERAS和多模式镇痛的随机试验，而不足以宣称任一药物可独立改善术后恢复性睡眠，为未来的研究提供清晰方向。

Abstract: Patients with gynecological malignancies may already have cancer-related insomnia, anxiety, depression, pain, and circadian disruption before surgery. Tissue injury, residual sedation, opioid exposure, postoperative nausea and vomiting, nighttime nursing, and ward environment can further compound postoperative sleep disturbance. Sleep disturbance interacts with pain sensitization, inflammation, delirium risk, mobilization, and quality of life, and is clinically relevant to enhanced recovery. This review no longer ranks remimazolam and midazolam as simply better or worse. Instead, it formulates a testable hypothesis that sedative choice may influence sleep indirectly through emergence, residual sedation, hemodynamics, and respiratory effects, and maps the contributions of pain, psychological stress, surgical approach, enhanced recovery after surgery (ERAS), and the hospital environment. Benzodiazepines remain important agents for perioperative sedation and anesthetic support. Remimazolam is an ultra-short-acting benzodiazepine rapidly metabolized by tissue esterases, whereas midazolam has a rapid onset, anxiolytic activity, and anterograde amnesia. Their effects on postoperative sleep architecture, next-day alertness, and longer-term sleep quality may differ. Direct evidence remains limited to gynecological laparoscopic cohorts not stratified by malignancy. In a randomized trial of 132 patients, remimazolam was associated with shorter total sleep time and a lower proportion of deep sleep on the first postoperative night, as well as slower emergence and PACU discharge than propofol. A separate study in elderly gynecological laparoscopic patients suggested fewer sleep disturbances, but publicly available reporting provides limited sample-size and effect-size detail. In older adults undergoing laparoscopic colorectal cancer surgery, a remimazolam-propofol combination was associated with faster awakening and fewer sleep disturbances, but this cannot substitute for a remimazolam-versus-midazolam comparison. Procedural-sedation trials found faster onset and alertness recovery and less post-procedure extra sleep with remimazolam than with midazolam, although dosing and clinical context differ from radical gynecologic oncology surgery. This review summarizes the clinical characteristics of postoperative sleep disturbance in patients with gynecological malignancies, combines pharmacological basis and existing clinical evidence, and deeply analyzes the methodological limitations and evidence gaps of current research. Current evidence therefore supports stratified, adequately blinded randomized trials with standardized ERAS and multimodal analgesia, but does not establish that either drug independently improves restorative postoperative sleep, which provides a clear direction for future research.